Trending...
- Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
- A New Era Of Social Networking Is Here !
- Poetry Quarterly Returns in Print With Its Fall 2026 Issue, Featuring 42 Poets
LANGHORNE, Pa. ~ Techdow USA Inc., a vertically integrated generic injectables company, has announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.
Darren Alkins, Chief Executive Officer of Techdow USA, said "We are excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin. Our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing."
The launch of Enoxaparin will compliment Techdow USA's existing Heparin Sodium injection business which was launched in 2022. According to IQVIA Health for the 12 months ending December 2022, Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million.
Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs. To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information visit www.techdowusa.com.*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC
More on The PennZone
Techdow USA Inc., a growing market leader in the generic injectables industry, has announced that its product Enoxaparin Sodium (Preservative Free) in Prefilled Syringes has been approved by the FDA for use in the U.S market. Darren Alkins, Chief Executive Officer of Techdow USA expressed his excitement about bringing this critical product to institutions, retail and other networks that need a safe, affordable and reliable source of Enoxaparin with competitive pricing options available through their U.S and global networks as well as being a long term reliable resource for the marketplace .
The launch of Enoxaparin compliments Techdow USA's existing Heparin Sodium injection business which was launched in 2022 with IQVIA Health reporting US brand and generic sales for this product at approximately $550 million for the 12 months ending December 2022 .
Techdow USA is continuing its efforts to expand its product portfolio and pipeline to better serve patient and customer needs while also being one of the fastest growing companies in the US generic pharmaceutical industry specializing in selling generic injectable pharmaceuticals . To report SUSPECTED ADVERSE REACTIONS contact Hepalink USA , Inc./Techdow USA , Inc . at 1 - 888 - 355 - 1375 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch . For more information visit www . techdowusa . com * Lovenox® is a registered trademark of Sanofi - Aventis U . S . LLC
Darren Alkins, Chief Executive Officer of Techdow USA, said "We are excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin. Our U.S. and global networks will help ensure reliable Enoxaparin supply, while offering competitive pricing."
The launch of Enoxaparin will compliment Techdow USA's existing Heparin Sodium injection business which was launched in 2022. According to IQVIA Health for the 12 months ending December 2022, Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million.
Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry specializing in the sale of generic injectable pharmaceuticals and continues to work to expand their product portfolio and pipeline to better serve patient and customer needs. To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information visit www.techdowusa.com.*Lovenox® is a registered trademark of Sanofi-Aventis U.S. LLC
More on The PennZone
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Veteran Antiques Expert John Swahn Releases New Book: The Truth About Antiques
- Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy
- Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
Techdow USA Inc., a growing market leader in the generic injectables industry, has announced that its product Enoxaparin Sodium (Preservative Free) in Prefilled Syringes has been approved by the FDA for use in the U.S market. Darren Alkins, Chief Executive Officer of Techdow USA expressed his excitement about bringing this critical product to institutions, retail and other networks that need a safe, affordable and reliable source of Enoxaparin with competitive pricing options available through their U.S and global networks as well as being a long term reliable resource for the marketplace .
The launch of Enoxaparin compliments Techdow USA's existing Heparin Sodium injection business which was launched in 2022 with IQVIA Health reporting US brand and generic sales for this product at approximately $550 million for the 12 months ending December 2022 .
Techdow USA is continuing its efforts to expand its product portfolio and pipeline to better serve patient and customer needs while also being one of the fastest growing companies in the US generic pharmaceutical industry specializing in selling generic injectable pharmaceuticals . To report SUSPECTED ADVERSE REACTIONS contact Hepalink USA , Inc./Techdow USA , Inc . at 1 - 888 - 355 - 1375 or FDA at 1 - 800 - FDA - 1088 or www . fda . gov / medwatch . For more information visit www . techdowusa . com * Lovenox® is a registered trademark of Sanofi - Aventis U . S . LLC
Filed Under: Business
0 Comments
Latest on The PennZone
- New Bethany, Provident Bank, Jaindl Farms and Lehigh Valley IronPigs Unite for Turkey Drive
- Grace Montessori School Awarded $56,180 to Support Scholarships for 15 Students
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- Brother Marcus Celebrates 400th Episode of The Elements of Inspiration Podcast
- USA Dental Edge Unveils Dental Intelligence
- The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- An AI Plays Kenshi Entirely by Itself, Live 23 Hours a Day, With an AI Host and Chat Voting
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
- Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
- Meals on Wheels of the Greater Lehigh Valley Raises Over $50,000 to Help Feed Local Seniors
- Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
- Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
- The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
- New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)